Merck And Co

Merck And Co, a US-based Pharmaceutical Preparation Manufacturing company, reported its latest carbon emissions data for 2024. The company's total Scope 1 emissions were approximately 721 million kg CO2e. Scope 2 emissions (market-based) were around 163 million kg CO2e, while location-based Scope 2 emissions were approximately 323.8 million kg CO2e. Scope 3 emissions totalled about 6.057 billion kg CO2e, including significant contributions from purchased goods and services (approximately 4.743 billion kg CO2e) and upstream transportation and distribution (approximately 423.7 million kg CO2e).

Looking back, in 2023, Merck And Co reported Scope 1 emissions of approximately 731.6 million kg CO2e, market-based Scope 2 emissions of about 170.1 million kg CO2e, and Scope 3 emissions of around 5.863 billion kg CO2e. In 2022, Scope 1 emissions were roughly 739.5 million kg CO2e, market-based Scope 2 emissions were about 217.3 million kg CO2e, and Scope 3 emissions stood at approximately 5.999 billion kg CO2e.

Merck And Co has set ambitious climate commitments. The company is committed to achieving net-zero greenhouse gas emissions across all Scopes (1, 2, and 3) by 2045, a target aligned with the Science Based Targets initiative (SBTi). In the near term, Merck And Co aims to reduce its Scope 1 and 2 operational GHG emissions by 46% by 2030, using a 2019 baseline. Furthermore, the company plans to reduce its value chain (Scope 3) GHG emissions by 30% by 2030, also against a 2019 baseline. Progress towards these goals includes a 12% reduction in Scope 1 and 2 emissions and a 4% decrease in Scope 3 emissions from the 2019 baseline as of 2023. Additionally, Merck And Co has committed to becoming carbon neutral across its operations (Scopes 1 and 2 GHG emissions) by 2025.